I have gone into detail as to what the criticisms of the trial are from other GBM experts. I did not rehash them in detail because my other article is still available
I didn’t “ignore” anything with respect to the authors. I refer you to my lengthy discourse on other phase 3 trials that have critiques. I have questions that have not been answered here, and I think that’s telling.
If you can answer the questions I posed, then you’ll understand why I don’t feel having 73 authors on a paper is worth as much as this board does. I won’t retype my arguments that continue to be ignored
And the criticism has come from parties with connections to TTF, a competing treatment, without any disclosure of these connections in their declarations when submitting their comments.
Market Data 
Markets 
AI
